ASCO25: MSD’s KRAS G12C drug shows early promise in Phase I
MSD’s investigational KRAS G12C inhibitor has shown signs of anti-tumour activity when used both alone and in combination with other oncology…
All articles by Abigail Beaney
Abigail Beaney
Abigail Beaney is the editor of Clinical Trials Arena. Abigail has expertise in clinical trial regulation, trial design, outsourcing, and cell and gene therapies. Abigail also has covered news and has a wealth of knowledge across several therapy areas including neurodegenerative, infectious and metabolic diseases. Abigail holds a first-class BA (Hons) degree in Journalism from the University of Central Lancashire in the United Kingdom. She has also obtained the National Qualification in Journalism through the UK's media industry body, the National Council for the Training of Journalists. Contact Abigail
-
-
ASCO25: Merck KGaA to seek approval of TGCT drug after Phase III success
Merck KGaA (Merck) is filing for global regulatory approvals of its CSF-1R inhibitor pimicotinib after it met the primary and all…
-
Power of collaboration more pertinent than ever says pharma experts
As the pharma industry navigates uncertainty caused by successive moves by the US administration, including international tariffs and drug pricing…
-
Apnimed to seek approval for sleep apnoea pill after Phase III success
Apnimed’s oral sleep apnoea therapy AD109 has met the primary endpoint in a Phase III trial, with hopes to file…
-
Are regulators keeping pace with AI adoption in clinical trials?
AI is increasingly being adopted by sponsors for various applications in clinical trials, including optimising trial design, identifying suitable patients…
-
GSK and iTeos drop anti-TIGIT drug following trial failure
GSK and iTeos are the latest companies to scrap a jointly developed anti-TIGIT drug after it failed to demonstrate a…
-
GLP-1RAs show anti-cancer benefits beyond weight loss
A study has found that glucagon-like peptide-1 receptor agonists (GLP-1RAs) offer anti-cancer benefits that extend beyond their role in promoting…
-
Novo Nordisk’s Sogroya matches Norditropin in children’s growth disorders
Novo Nordisk’s once-weekly Sogroya (somapacitan) has proved to be non-inferior to the once-daily growth hormone Norditropin (somatropin) in children’s growth…
-
Sanofi exec tells biotechs not to scrimp on clinical trial design
At a time when the biotech sector has been struggling with a lack of investment, some companies have had to…
-
European biotechs must understand US culture while seeking funding
At a time when the US is becoming more self-focused, European biotechs must understand and appreciate US culture when seeking…